Kelly E. McCann, MD, PhD

Kelly E. McCann, MD, PhD, is an assistant professor and breast medical oncologist at UCLA.

Articles

Managing Brain Metastases in HER2+ Breast Cancer: Second-Line Treatment Decisions

May 7th 2025

Panelists discuss how the presence of brain metastases influences treatment decisions in HER2-positive (HER2+) breast cancer, highlighting the DESTINY-Breast12 trial demonstrating trastuzumab deruxtecan’s (T-DXd) efficacy in patients with brain metastases.

Expert Perspectives on Navigating Treatment-Related Adverse Events With T-DXd

May 7th 2025

Panelists discuss how they manage adverse effects of trastuzumab deruxtecan (T-DXd), particularly focusing on nausea, fatigue, and the critical monitoring needed for interstitial lung disease (ILD), with recommendations for prophylactic antiemetics and frequent imaging.

Clinical Insights Into Treatment Approach for Metastatic HER+ mBC Patient Case

April 30th 2025

Panelists discuss how they approach treatment sequencing for HER2-positive (HER2+) metastatic breast cancer (mBC) after progression on first-line therapy, including considerations for trastuzumab deruxtecan and the impressive results from the PATINA trial adding CDK4/6 inhibitors to maintenance therapy.

Clinical Scenario I: 52-year-old Woman With Recurrent Metastatic HER2+ Breast Cancer

April 30th 2025

Panelists discuss how a 52-year-old elementary school teacher diagnosed with HER2-positive (HER2+) breast cancer achieved pathologic complete response with neoadjuvant therapy but experienced metastasis 18 months after completing treatment, requiring first-line metastatic therapy.

Treatment Planning for HER2+ Breast Cancer: The Role of Ovarian Function Suppression

April 28th 2025

Panelists discuss how ovarian suppression combined with endocrine therapy shows benefits for premenopausal patients with triple-positive breast cancer, particularly in younger, high-risk populations.

Optimizing Therapy in HR+/HER2+ Breast Cancer: Balancing Endocrine, HER2-Targeted, and Chemotherapy Options

April 28th 2025

Panelists discuss how treatment strategies for triple-positive breast cancer (hormone receptor [HR] positive and HER2 positive) differ from those for hormone receptor–negative, HER2-positive disease, with emphasis on balancing endocrine therapy, HER2-targeted therapy, and chemotherapy.

Dr McCann on the Increasing Use of TKIs for HER2+ Breast Cancer Brain Metastases

April 7th 2025

Kelly E. McCann, MD, PhD, discusses the benefit of using TKI combinations for patients with HER2-positive breast cancer and brain metastases.

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

March 31st 2025

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Dr McCann on the Ongoing Development of Tailored Treatment Regimens in HER2+ Breast Cancer

March 12th 2025

Kelly E. McCann, MD, PhD, discusses several targeted approaches under investigation in HER2-positive breast cancer.

Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases

February 13th 2025

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

August 6th 2024

A panel of experts offer future perspectives in HR+ breast cancer.

Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer

August 6th 2024

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06

July 29th 2024

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer

July 29th 2024

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

July 29th 2024

A panel of experts discuss navigating 2L treatment strategies.

Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer

July 29th 2024

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.

Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer

July 8th 2024

A panel of experts discuss treatment updates in regards to CDK4/6 inhibitors.

Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA

July 8th 2024

A panel of experts discuss the potential of individual tumor sequencing with bespoke testing methodologies.

Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer

July 1st 2024

A panel of experts give perspectives on optimizing biomarker testing in Advanced HR+/HER2- Breast Cancer.

Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer

July 1st 2024

A panel of experts discuss advancements in adjuvant therapy for early-stage breast cancer.